Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -435.70% is 70% above its 5-year average of -1437.24%, near the high end of its 5-year range (-4316.26%–-250.22%).
43.12% above its 12-month average of -765.98%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -429.50%.
NET PROFIT MARGIN
-435.70%
NET PROFIT MARGIN AVG TTM
-765.98%
NET PROFIT MARGIN AVG 3Y
-1065.33%
NET PROFIT MARGIN AVG 5Y
-1437.24%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+43.12%
CURRENT VS 3Y AVG
+59.10%
CURRENT VS 5Y AVG
+69.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-167476.92%
vs the sector median at left
Nyxoah S.A.
Market Cap
$143.10M
Net Profit Margin
-435.70%
TTM Avg
-765.98%
3Y Avg
-1065.33%
5Y Avg
-1437.24%
Market Cap
$143.60M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$143.84M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$146.27M
Net Profit Margin
163.32%
TTM Avg
-34.49%
3Y Avg
-63.76%
5Y Avg
-75.19%
Market Cap
$146.28M
Net Profit Margin
-39.55%
TTM Avg
-86.23%
3Y Avg
-76.35%
5Y Avg
-60.08%
Market Cap
$139.84M
Net Profit Margin
-395.25%
TTM Avg
-276.53%
3Y Avg
-199.61%
5Y Avg
-174.03%
Market Cap
$146.62M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-85.02%
Market Cap
$146.67M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-644.95%
Market Cap
$139.47M
Net Profit Margin
-153.61%
TTM Avg
-101.12%
3Y Avg
-50.56%
5Y Avg
-33.71%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nyxoah S.A. (NYXH) | $143.10M | -435.70% | -765.98% | -1065.33% | -1437.24% |
| Protara Therapeutics, Inc. (TARA)vs › | $143.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 163.32% | -34.49% | -63.76% | -75.19% |
| Codexis, Inc. (CDXS)vs › | $146.28M | -39.55% | -86.23% | -76.35% | -60.08% |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | -395.25% | -276.53% | -199.61% | -174.03% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | 0.00% | 0.00% | 0.00% | -85.02% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $146.67M | 0.00% | 0.00% | 0.00% | -644.95% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -153.61% | -101.12% | -50.56% | -33.71% |
| Immuneering Corporation (IMRX)vs › | $139.04M | 0.00% | 0.00% | -3984.32% | -3047.80% |
Operating Margin
-827.8%
Net Profit Margin
-435.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -429.50% |
| 2026-03-31 | -250.22% |
| 2025-12-31 | -416.60% |
| 2025-09-30 | -1195.74% |
| 2025-06-30 | -1537.84% |
| 2025-03-31 | -2103.76% |
| 2024-12-31 | -1357.80% |
| 2024-09-30 | -1347.39% |
| 2024-06-30 | -1702.20% |
| 2024-03-31 | -975.10% |
| 2023-12-31 | -597.20% |
| 2023-09-30 | -779.92% |
| 2023-06-30 | -1156.01% |
| 2023-03-31 | -2700.91% |
| 2022-12-31 | -1017.29% |
| 2022-09-30 | -3428.57% |
| 2022-06-30 | -533.69% |
| 2022-03-31 | -1015.30% |
| 2021-12-31 | -2117.97% |
| 2021-09-30 | -4316.26% |
| 2021-06-30 | -4081.76% |
| 2021-03-31 | -3064.32% |
| 2020-12-31 | -11514.49% |
| 2020-09-30 | -11514.49% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
